Menu
ncarol.com
  • Home
  • Business
  • Books
  • Real Estate
  • Financial
  • New Release
  • Sports
  • Arts
  • Technology
ncarol.com

Aerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET
ncarol.com/10174876

Trending...
  • Virtual Workplace Platform Developer REACH Expands Executive Team, Positioning the Company to Drive International Growth
  • Key Risk Names Whitney Neal as Vice President, Human Resources
  • Fathym announces the addition of Sergio Sotolongo to its board of directors
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan, Chief Executive Officer, along with Peter Lang, Chief Financial Officer, and Dr. Gary Sternberg, Chief Medical Officer, will present at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. Eastern Time in New York City, NY.



Date:





June 10, 2022



Presentation Time:





10:30 a.m. ET



Webcast:





http://investors.aeriepharma.com



Replay Availability:





Until September 8, 2022


About Aerie Pharmaceuticals, Inc.

Aerie is a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). Aerie's first novel product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie's second novel product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil (0.02%) and latanoprost ophthalmic solution (0.005%)), was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage. More information about Rocklatan®, including the product label, is available at www.rocklatan.com. More information on Aerie Pharmaceuticals is available at www.aeriepharma.com.

More on ncarol.com
  • WELL Health Adds New Executives to Drive Continued Growth
  • Emily "Ellie" Spencer joins Spencer Properties full time!
  • Indie Brand Vow Beauty Enters Walmart
  • North Carolina: Governor Cooper Signs Three Bills into Law
  • James Postrasija, CEO of Order Food Online on Platform Features/Benefits

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "exploring," "pursuing" or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements in this release include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our commercial franchise and our pipeline, any guidance or timelines and our ongoing and anticipated preclinical studies and clinical trials. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, industry change and other factors beyond our control, and depend on regulatory approvals and economic and other environmental circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We discuss many of these risks in greater detail under the heading "Risk Factors" in the quarterly and annual reports that we file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

More on ncarol.com
  • Disney Good Neighbor Hotel Lulu is Open for the Summer
  • EPA's Renewable Fuel Standard Pathways Expand to Include Greasezilla® Advanced Biofuel as RIN-Qualified Feedstock
  • Aspiring To Excellence Continues at Globe Star with CARF Accreditation
  • JKS Financial Sponsors Program To Teach High School Students Investment Skills
  • Gary Kevin Coats Raleigh, NC Top 10 Tips for Homebuyers

Contacts

Media:
Carolyn McAuliffe
cmcauliffe@aeriepharma.com
(949) 526-8733

Investors:
LifeSci Advisors on behalf of Aerie Pharmaceuticals, Inc.
Hans Vitzthum
hans@lifesciadvisors.com
(617) 430-7578
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Go-Forth Pest Control Named to 2022 List of Great Employers to Work for in North Carolina
  • Mutual Aid Ambulance Service Partners with Excela Health for Paramedic Training Program
  • In2Scuba Diving Co. of Maui introduces its exclusive beginner scuba diving lessons
  • Always Ontime: Chaos City - Super Hero Graphic Novel with Neal Adams Cover Launches from Panopolis Metaverse
  • New Hampshire Becomes the 15th State to Require Personal Finance as a Core Academic Subject
  • Virtual Workplace Platform Developer REACH Expands Executive Team, Positioning the Company to Drive International Growth
  • Amwins Partners with FusionMGA Providing Exclusive Access to Strategic Cyber Capacity
  • Health Advisory: Protecting Yourself and Others from Monkeypox
  • Piedmont Lithium and Sayona Mining Formalize Restart Plans for North American Lithium in Quebec
  • Kindle FREE June 28-29: Powerful new memoir from Santa Molina-Marshall poised to help heal abuse victims through inspiring storytelling
  • GoodLoan.io announces new program to unlock up to $500,000 for Home Equity Investment
  • Beck Properties Group Hires Professional Marketing Team
  • Cosplay Universe" Documentary to Premiere at Anime Expo & in Theaters this Summer
  • Kano Laboratories, Makers of Kroil, Announces Refreshed Branding for Extended Line of Industrial Product Solutions
  • Fathym announces the addition of Sergio Sotolongo to its board of directors
  • Key Risk Names Whitney Neal as Vice President, Human Resources
  • Prolific Author Tam R. Luc Celebrates Positive Title IX Achievements and Pushes Businesswomen to the Next Level with Boss Up Summit
  • Avion Medical Skin Centres to offer innovative treatment for non-melanoma skin cancer patients
  • Medical and Dental SEO Specialists 2022 award
  • Launch of Def Leppard beauty collection creating Hysteria in the makeup industry
_catLbl0 _catLbl1

Popular on ncarol.com

  • Order Food Online Featured Startup at Collision Conference Toronto 2022
  • Skin EX Introduces Their Latest Technology for Beauty Rejuvenation
  • Linksys and Axiros Collaborate to Provide Whole Home Coverage and Deep Insight into WiFi Network
  • KRISPY KREME® Delivers the Fresh Vibes of Summer with New ‘Pick of the Patch’ Berry Doughnuts
  • Terrorism is again on the rise warnings in new TERROR STRIKES book release
  • North Carolina: Rural Communities Awarded American Rescue Plan Transformation Grants to Boost Local Economies
  • Arkansas Medical, Dental, and Pharmaceutical Association, Inc. (AMDPA) Announces New President in First In-Person Scientific Session in Three Years
  • The National Association for Legal Support Professionals 2022 National Legal Education Conference
  • Millennium Trailers Announces It's All New Bumper Pull Living Quarter Trailers
  • Gov. Murphy, Mayor Fulop & Regional Leaders In-Person June 23rd at The Jersey City Summit for Real Estate Investment

Similar on ncarol.com

  • 65% of Today's Workforce Is Actively Looking for Another Job; Culture Over Everything Is the Solution
  • Signs By Veterans and Savage Shakers Founder Announces Sponsorship for #TEAMUSA Para-Athlete Brian Conwell
  • WELL Health Adds New Executives to Drive Continued Growth
  • James Postrasija, CEO of Order Food Online on Platform Features/Benefits
  • EPA's Renewable Fuel Standard Pathways Expand to Include Greasezilla® Advanced Biofuel as RIN-Qualified Feedstock
  • Altdefy 383K Review $16,987 Bonus
  • Cove Data Protection for Microsoft 365 Surpasses One Million Unique Users
  • Life Edit Therapeutics Appoints Joy A. Cavagnaro to Its Scientific Advisory Board
  • Old Dominion Freight Line to Webcast Second Quarter 2022 Conference Call
  • OrbitalRX Joins End Drug Shortages Alliance
Copyright © 2022 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute